Test Price
1,000 AED✅ Home Collection Available
Prenatal Alpha Thalassemia Mutation Screening (3 Common Mutations) – Dubai, UAE | DNA Labs UAE
Executive Summary & Core Metrics
This molecular prenatal screening detects the three most prevalent alpha-thalassemia deletions (--SEA, -α3.7, -α4.2) in fetal samples with a diagnostic sensitivity exceeding 99.9%, processed under ISO 9001:2015 accreditation. The test is performed exclusively within accredited hospital facilities due to the invasive nature of specimen collection. Direct billing verification is available via WhatsApp at +971 54 548 8731, and telephonic post-test clinical guidance is provided by our genetics team.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Molecular Processing.
- Collection Protocol: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This prenatal screening assay targets the three common alpha-globin gene deletions responsible for alpha-thalassemia in populations with Mediterranean, Southeast Asian, and Middle Eastern ancestry. Using endpoint polymerase chain reaction (PCR) on fetal genomic DNA extracted from amniotic fluid, chorionic villi, or cord blood, the test conclusively identifies carrier and affected status. Unlike hematological indices or hemoglobin electrophoresis, which provide only indirect presumptive evidence, this molecular method delivers definitive genotypic results within 10–12 working days, enabling informed reproductive counseling and perinatal management.
| Feature | Our Test (DNA Labs UAE) | Standard Hematological Screening (CBC / HPLC) |
|---|---|---|
| Precision | Molecular DNA deletion detection (99.9% sensitivity) | Indirect hemoglobin analysis; may miss silent carriers and cannot distinguish alpha genotypes |
| Methodology | End-Point PCR (ISO 9001:2015 Certified) | Complete blood count & HPLC; not definitive for alpha-thalassemia genotyping |
| Turnaround Time | 10–12 Working Days (confirmation) | 1–2 Days (presumptive only) |
Physician Insight & Safety Protocols
“As a DHA-licensed Consultant Medical Genetics, I recommend this molecular screening for at-risk couples planning a pregnancy or in early gestation. Definitive identification of the three common alpha-thalassemia deletions empowers accurate genetic counseling and obstetrical planning. However, a negative result does not exclude rare or non-deletional mutations; therefore, post-test consultation with a genetics specialist remains essential. Always correlate molecular findings with fetal ultrasound and maternal hematological parameters.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Advisory Pre-Test Guidance
Medication & Supplement Advisory
Do not discontinue any prescribed medication or prenatal supplement without first consulting your managing obstetrician or genetic counselor. This molecular screening is a diagnostic adjunct and does not replace ongoing clinical care or therapeutic regimens.
Exclusion Criteria & Emergency Red Flags
Contraindications for Invasive Sampling
- Amniocentesis or chorionic villus sampling is contraindicated in the presence of active vaginal bleeding, amniotic fluid leakage, documented chorioamnionitis, or infection at the proposed puncture site.
- If you experience severe abdominal pain, fever, persistent uterine contractions, or leakage of fluid following an invasive procedure, seek immediate emergency medical attention at the nearest hospital.
- This test is not suitable for patients currently on anticoagulant therapy without prior clearance from both the managing obstetrician and the interventional specialist.
Patient FAQ & Clinical Guidance
1. What is the accuracy of this prenatal alpha-thalassemia screening?
Our endpoint PCR technology achieves a diagnostic sensitivity of 99.9% for the three targeted alpha-globin deletions (--SEA, -α3.7, -α4.2), verified under ISO 9001:2015 laboratory accreditation. Nonetheless, rare non-deletional or point mutations not included in the panel may produce a false-negative result; therefore, follow-up genetic counseling is strongly recommended to contextualize the findings.
2. Which sample type is required and how is it collected?
The test requires a fetal genomic DNA sample obtained via amniocentesis (amniotic fluid), chorionic villus sampling (chorionic villi), or cordocentesis (cord blood). These are invasive procedures performed exclusively by a qualified obstetrician within an accredited hospital setting. Mobile home phlebotomy is not available for this test due to the clinical complexity and safety requirements of fetal sampling.
3. How will I receive my results and who will explain them?
Results are delivered via encrypted email within 10–12 working days. A dedicated telephonic consultation with our Consultant Medical Genetics team is scheduled to interpret the molecular findings, address your questions, and coordinate follow-up care with your obstetrician and genetic counselor.
UAE Regulatory & Data Privacy Adherence
Legal & Accreditation Framework
This service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability regarding patient safety and informed consent. Laboratory processing is performed under ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139). DHA Facility License: 1143. Direct billing verification is available via WhatsApp at +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | Prenatal Alpha Thalassemia Mutation Screening (3 Common Mutations) |
| Price (AED) | 1,000 |
| Turnaround Time | 10–12 Working Days |
| Sample Type / Matrix | Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | End-Point PCR (ISO 9001:2015 Certified) |
| ICD-10-CM Code | Z13.0 |
| LOINC Code | 21671-8 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians